Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in early 2009.

"While the primary goal of this study is to demonstrate safety of PI-2301 in multiple sclerosis patients, we believe that this clinical trial is one of the most comprehensive looks at the pharmacologic effects of any immunomodulator in patients suffering from autoimmune diseases," stated Thomas P. Mathers, President and CEO of Peptimmune. Mr. Mathers will be presenting an overview of the PI-2301 clinical program at the BIO 2008 Business Forum, Wednesday, June 18th, at 9:00 a.m. PDT at the San Diego Convention Center, Room 2.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechan
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014   LabStyle Innovations Corp . (OTCQB: ... today announced that it has closed a $4.2 ... preferred stock and warrants.  No placement agent was ... LabStyle expects to secure net proceeds of approximately ... LabStyle intends to use the net proceeds from ...
(Date:9/23/2014)... , Sept. 23, 2014  Global Discovery Biosciences, ... conquer some of the biggest healthcare challenges, announces their ... highly accurate blood test for the early detection of ... cause of cancer death. Typically, the symptoms and subsequent ... of cancer, where the chance of a cure has ...
(Date:9/23/2014)... , September 23, 2014 ... l,automobile, la santé, le ferroviaire ou encore ... connectées, donneront progressivement accès à leurs données. ... nombreux capteurs installés au cœur des voitures, ... plusieurs dizaines de milliards le nombre de ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5Global Discovery Biosciences Announces Collaboration with IPMD, Inc. to Develop Innovative Aptamer-Based Blood Test for the Early Detection of Lung Cancer 2Altran transforme le big data du monde industriel en nouveau business 2
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Trevera ... services market. Included are Oracle Managed Services ... Trevera supports all versions of Oracle E-Business Databases ... releases. , Trevera has announced a significant ... that need help with their software technology management, ...
(Date:9/23/2014)... September 23, 2014 The Sloane ... in Singapore and Malaysia providing advanced aesthetic dermatology ... powder to its impressive skin care repertoire. Specially ... skin’s defences against the evil forces of aging, ... glow simultaneously, this new addition is revolutionizing the ...
(Date:9/23/2014)... NC (PRWEB) September 23, 2014 ... a national research university located In the Piedmont ... joined UNCG as co-director of the Center for ... bioanalytical chemistry, comes to UNCG after nearly a ... Northwest National Laboratory, Biological Sciences Division. , ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
Breaking Medicine News(10 mins):Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3
... development of autism in infants, comparing the behavior of the ... developing normally, has found that the nascent symptoms of the ... communicative babbling are not present at 6 months, but ... of the first year of life. Researchers conducted the ...
... have identified a mechanism used by the tuberculosis bacterium ... a compound that blocks the bacterium,s ability to survive ... to treat tuberculosis. Zhong-Yin Zhang, Ph.D., Robert A. ... and Molecular Biology, and his colleagues revealed the biochemical ...
... , Feb. 15 In just two weeks, online ... helping the organization come in first with more than 49 percent ... the Super Love Sender giving campaign on the Target Facebook® page. ... on February 14, 2010 , invited the online community and ...
... (OHRI) and the University of Ottawa suggests that stem cells ... tissue development. The study, published in Proceedings of the ... researchers think about tissue development, stem cells and cancer. ... all our genes. Certain chemicals and UV light can break ...
... finds , MONDAY, Feb. 15 (HealthDay News) --People who think ... of cigarettes are kidding themselves, a new study shows. , ... Dr. R. Graham Barr, assistant professor of medicine and epidemiology ... report in the Feb. 16 issue of Annals of ...
... effect on squamous cell carcinoma , MONDAY, Feb. 15 ... of NSAID painkillers might help reduce cancer risk, a ... protection against a common skin cancer. , Previous research ... such over-the counter medications as Advil, Motrin, aspirin, Celebrex ...
Cached Medicine News:Health News:Autism's earliest symptoms not evident in children under 6 months 2Health News:Autism's earliest symptoms not evident in children under 6 months 3Health News:Autism's earliest symptoms not evident in children under 6 months 4Health News:IU research team discovers TB disease mechanism and molecule to block it 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 3Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 4Health News:New study suggests stem cells sabotage their own DNA to produce new tissues 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3Health News:NSAIDs Won't Shield Against Skin Cancer 2Health News:NSAIDs Won't Shield Against Skin Cancer 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: